FacebookTwitterGoogle+RedditEmail

Big Pharma Has A Rare Week

by MARTHA ROSENBERG

The sound you hear is Pharma swinging from the rafters. Two news stories this week may reinfuse revenue streams in an industry whose blockbuster pill “bubble” has burst.  As Lipitor, Seroquel, Zyprexa, Singulair, Concerta and several other drugs have lost patent protection, Pharma is shedding both employees and ad campaigns. WebMD, the voice of Pharma on the Web, announced it would cut 250 positions in December and medical journals like the Journal of the American Medical Association (JAMA) and New England Journal of Medicine are noticeably thinner without the Pharma ads that have leavened them for years.

Vitamin D and calcium will not protect older women from fractures, a government task force reported this week, in the Annals of Internal Medicine. The U.S. Preventive Services Task Force “recommends against daily supplementation with 400 IU or less of vitamin D3 and 1000 mg or less of calcium for the primary prevention of fractures” and  also recommends that older women, and younger ones with risk factors, be screened for osteoporosis.

While the report does not recommend expensive drugs or seem to be penned by Pharma consultants, its message is still good news for Pharma whose anti-osteoporosis drugs carried it through the 2000s.  “Don’t rely on just Vitamin D and calcium” and “get a bone scan!” were the marketing messages of the bone drugs Boniva, Fosamax and Actonel.

According to published reports, Merck, who launched the bone drug category with its Fosamax, single handedly initiated the “bone scan” craze foisted on middle aged and older women, including setting up a bone “institute” to secure Medicare reimbursement for the scans which were driving Fosamax sales.

Pharma even created the term “osteopenia”–at risk of osteoporosis–to sell the now discredited bone drugs, which are linked to esophageal cancer, osteonecrosis of the jaw, irregular heart beat, pain and actually causing fractures. Subsequent medical reports found the heavily marketed bone scans only benefit 10 percent of women who get them.

In more good news for Pharma this week, Genentech’s drug for allergic asthma, Xolair, co-marketed with Novartis, was trumpeted as having a new possible indication of treating patients with chronic hives or chronic idiopathic urticaria, reported the New York Times. If approved for the new indication, chronic idiopathic urticaria will likely became a major U.S. health problem to be advertised on TV like restless legs syndrome. Ka-ching.

Genetically engineered drugs like Xolair (called monoclonal antibodies) cost as much as $20,000 a year and cause TB, cancers and super infections according to their labels because they suppress the immune system. Xolair was investigated by the FDA for links to heart attack and stroke and 77 people who took Xolair had life-threatening allergic responses in a year and a half, according to FDA reports.

Some of the clinical tests to determine Xolair’s safety were conducted at Vivra which was investigated twice by the FDA for procedural irregularities. Trials of Xolair and at least seven other drugs were corrupted by protocol violations and outright falsifications, according to a former clinical research subinvestigator who worked at the facility. San Mateo, Calif.-based Vivra Asthma & Allergy was the nation’s largest respiratory disease physician practices until a merger with Lakewood, Colo.-based Gambro in 1997 and with El Segundo, Calif.-based DaVita in 2005.

There is even a genetically engineered monoclonal antibody drug called Prolia to treat osteoporosis that costs $1,650 a year now that we know Vitamin D and calcium don’t work.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

CounterPunch Magazine

minimag-edit

bernie-the-sandernistas-cover-344x550

zen economics

July 26, 2017
John W. Whitehead
Policing for Profit: Jeff Sessions & Co.’s Thinly Veiled Plot to Rob Us Blind
Pete Dolack
Trump’s Re-Negotiation Proposal Will Make NAFTA Worse
George Capaccio
“Beauty of Our Weapons” in the War on Yemen
Ramzy Baroud
Fear and Trepidation in Tel Aviv: Is Israel Losing the Syrian War?
John McMurtry
Brexit Counter-Revolution Still in Motion
Ted Rall
The Democrats Are A Lost Cause
Tom Gill
Is Macron Already Faltering?
Ed Kemmick
Empty Charges Erode Trust in Montana Elections
Rev. William Alberts
Fake News? Or Fake Faith?
James Heddle
The Ethics and Politics of Nuclear Waste are Being Tested in Southern California
Binoy Kampmark
Slaying in Minneapolis: Justine Damond, Shooting Cultures and Race
Jeff Berg
Jonesing for Real Change
Jesse Jackson
The ‘Voter Fraud’ Commission Itself is Fraudulent
July 25, 2017
Paul Street
A Suggestion for Bernie: On Crimes Detectable and Not
David W. Pear
Venezuela on the Edge of Civil War
John Grant
Uruguay Tells US Drug War to Take a Hike
Charles Pierson
Like Climate Change? You’ll Love the Langevin Amendment
Linda Ford
Feminism Co-opted
Andrew Stewart
Any Regrets About Not Supporting Clinton Last Summer?
Aidan O'Brien
Painting the Irish Titanic Pink
Rob Seimetz
Attitudes Towards Pets vs Attitudes Towards the Natural World
Medea Benjamin
A Global Movement to Confront Drone Warfare
Norman Solomon
When Barbara Lee Doesn’t Speak for Me
William Hawes
What Divides America From the World (and Each Other)
Veteran Intelligence Professionals for Sanity
Was the “Russian Hack” an Inside Job?
Chandra Muzaffar
The Bilateral Relationship that Matters
Binoy Kampmark
John McCain: Cancer as Combatant
July 24, 2017
Patrick Cockburn
A Shameful Silence: Where is the Outrage Over the Slaughter of Civilians in Mosul?
Robert Hunziker
Extremely Nasty Climate Wake-Up
Ron Jacobs
Dylan and Woody: Goin’ Down the Road Feelin’ Bad
Dan Glazebrook
Quantitative Easing: the Most Opaque Transfer of Wealth in History
Ellen Brown
Saving Illinois: Getting More Bang for the State’s Bucks
Richard Hardigan
The Media is Misleading the Public on the Al-Asqa Mosque Situation
Matthew Stevenson
Travels in Trump’s America: Memphis, Little Rock, Fayetteville and Bentonville
Ruth Fowler
Fire at Grenfell
Ezra Kronfeld
The Rights of Sex Workers: Where is the Movement to Legalize Prostitution
Mark Weisbrot
What Venezuela Needs: Negotiation Not Regime Change
Binoy Kampmark
From Spicy to the Mooch: A Farewell to Sean Spicer
Wim Laven
Progress Report, Donald Trump: Failing
Weekend Edition
July 21, 2017
Friday - Sunday
Kevin Zeese
Green Party Growing Pains; Our Own Crisis of Democracy
Jeffrey St. Clair
Red State, Blue State; Green State, Deep State
Paul Street
“Inclusive Capitalism,” Nancy Pelosi, and the Dying Planet
Anthony DiMaggio
Higher Education Fallacies: What’s Behind Rising Conservative Distrust of Learning?
Andrew Levine
Why Republicans Won’t Dump Trump Anytime Soon
Michael Colby
Ben & Jerry’s Has No Clothes
FacebookTwitterGoogle+RedditEmail